期刊文献+

生长抑素类似物在垂体促甲状腺激素瘤诊断和治疗中的作用 被引量:15

Octreotide in the diagnosis and treatment of pituitary thyrotropin-secreting adenoma
原文传递
导出
摘要 目的探讨生长抑素类似物奥曲肽在垂体促甲状腺素(TSH)瘤诊断和治疗中的作用。方法系统报告北京协和医院诊治的1例垂体TSH大腺瘤患者临床特点,采用99mTc-奥曲肽显像和鞍区MRI对肿瘤进行准确定位诊断。给予奥曲肽0.1mg,每8h皮下注射,10d,观察TSH水平和肿瘤大小的变化,经口鼻蝶窦行垂体瘤切除术,观察手术效果,并进行相关文献复习。结果TSH瘤奥曲肽显像呈阳性。单纯抗甲状腺药物治疗难以使甲状腺功能完全正常。奥曲肽治疗能快速有效使甲状腺功能控制至正常,经10d奥曲肽治疗,垂体肿瘤由3.0cm×2.0cm×2.5cm缩小至2.0cm×2.0cm×1.5cm,甲状腺肿大由Ⅲ度缩小为Ⅱ度。结论99mTc-奥曲肽显像可作为TSH瘤定位诊断的方法之一。奥曲肽治疗能有效控制继发性甲状腺功能亢进并缩小TSH瘤体积,可用作TSH瘤的常规手术前准备。 Objective To evaluate the efficacy of octreotide in the diagnosis and treatment of pituitary thyrotropin (TSH)-secreting adenoma. Methods A 34-year man presented with central hyperthyroidism and pituitary TSH-secreting macroadenoma was reported. ^99mTc-octreotide scan and magnetic resonance imaging were completed to make the location diagnosis of the adenoma. Octreotide in 0. 1 mg dose was subcutaneosly injected every 8 hours for 10 days. Serum TSH level and tumor size were observed and trans-sphenoidal adenoma resection was completed. Results Pituitary TSH-secreting adenoma displayed positive sign in ^99mTc-octretide scan. Antithyroid drug was of no help in depressing thyroid function to normal. However, octreotide treatment could revert thyroid function to normal rapidly. A significant shrinkage of tumor mass from 3.0 cm × 2. 0 cm ×2. 5 cm to 2. 0 cm × 2. 0 cm × 1.5 cm was observed and a shrinkage of thyroid gland from Ⅲ to Ⅱ also observed. Conclusions ^99m Tc-octretide scan is one of the useful tools for location diagnosis of TSH-secreting adenoma. Octreotide can effectively control central hyperthyroid and make tumor shrink, and it can be a satisfactory method of preoperative preparation for TSH- secreting adenoma.
出处 《中华内科杂志》 CAS CSCD 北大核心 2006年第11期910-913,共4页 Chinese Journal of Internal Medicine
关键词 促甲状腺素 垂体肿瘤 奥曲肽 治疗 Thyrotropin Pituitary neoplasms Octreotide Treatment
  • 相关文献

参考文献7

  • 1Dhillon KS,Cohan P,Kelly DF,et al.Treatment of hyperthyroidism associated with thyrotropin-secreting pituitary adenomas with iopanoic acid.J Clin Endocrinol Metab,2004,89:708-711. 被引量:1
  • 2Socin HV,Chanson P,Delemer B,et al.The changing spectrum of TSH-secreting pituitary adenomas:diagnosis and management in 43 patients.Eur J Endocrinol,2003,148:433-442. 被引量:1
  • 3Beck-Peccoz P,Persani L.Medical management of thyrotropin-secreting pituitary adenomas.Pituitary,2002,5:83-88. 被引量:1
  • 4Brucker-Davis F,Oldfield EH,Skarulis MC,et al.Thyrotropin-secreting pituitary tumors:diagnostic criteria,thyroid hormone sensitivity,and treatment outcome in 25 patients followed at the National Institutes of Health.J Clin Endocrinol Metab,1999,84:476-486. 被引量:1
  • 5Beck-Peccoz P,Brucker-Davis F,Persani L,et al.Thyrotropin-secreting pituitary tumors.Endocr Rev,1996,17:610-638. 被引量:1
  • 6Erem C,Hacihasanoglu A,Sari A,et al.A rare case and a rapid tumor response to therapy:dramatic reduction in tumor size during octreotide treatment in a patient with TSH-secreting pituitary macroadenoma.Endocrine,2004,25:141-145. 被引量:1
  • 7Kuhn JM,Arlot S,Lefebvre H,et al.Evaluation of the treatment of thyrotropin-secreting pituitary adenomas with a slow release formulation of the somatostatin analog lanreotide.J Clin Endocrinol Metab,2000,85:1487-1491. 被引量:1

同被引文献65

引证文献15

二级引证文献27

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部